Vassallo C, Canali B, Fiorentino F, Morelli P, Ripoli S, Fioravanti L. Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy. AboutOpen [Internet]. 2023 Oct. 2 [cited 2024 Jul. 3];10(1):103-9. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2609